Block the survival signals the tumour's neighbours provide
Cancer cells can survive a drug because surrounding normal cells feed them growth signals. Blocking those signals could make existing drugs work better and longer.
Fibroblast- and macrophage-derived factors including HGF, FGFs and neuregulin rescue tumour cells from targeted therapy in co-culture and in vivo, an effect largely invisible in monoculture screens. Environment-mediated resistance argues for combining targeted agents with blockade of the specific rescuing ligand or its receptor, selected by profiling the tumour's own stroma rather than the tumour cells alone.
- Acquired resistance to every therapy · Nearly every targeted therapy stops working within months to a few years as the tumour adapts.
- Cold tumours and the immunosuppressive microenvironment · Most tumours keep the immune system out or asleep, so immunotherapy helps only a minority.
Pages like this
not linked directly; found by shared links- TrialHERTHENA-Lung02
Shares Patritumab deruxtecan, HER3.
- PersonHelena A. Yu
Shares Patritumab deruxtecan, HER3.
- IdeaMake every cold tumour hot: a coordinated programme to reprogramme immune-excluded tumours
Shares FAP, Single-cell & spatial profiling, Cold tumours and the immunosuppressive microenvironment.
- IdeaMatch therapy to the type of scar-forming cell in the tumour
Shares FAP, Single-cell & spatial profiling, Cold tumours and the immunosuppressive microenvironment.
- IdeaRe-map the tumour's surface proteins before choosing the next antibody drug
Shares HER3, Single-cell & spatial profiling, Acquired resistance to every therapy.
- IdeaFind the parts of a tumour the drug never reaches
Shares Single-cell & spatial profiling, Acquired resistance to every therapy.
- TechnologyTargeting tumour mechanics and pressure
Shares FAP, Single-cell & spatial profiling.
- IdeaAdd a drug when the blood test turns, without stopping the one that works
Shares MET, Acquired resistance to every therapy.